Glucose-dependent insulinotropic polypeptide (GIP; tirzepatide) use also achieved some insulin sensitivity improvement in T2D, although again it is unknown if this acted at the level of the liver (127). The gene discussed is GIP; the disease is type 2 diabetes mellitus.